SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-21-000038
Filing Date
2021-08-05
Accepted
2021-08-05 16:10:02
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ctic-20210805.htm   iXBRL 8-K 37289
2 EX-99.1 ex991earningsreleaseq22021.htm EX-99.1 67868
6 imagea15.jpg GRAPHIC 5087
  Complete submission text file 0000891293-21-000038.txt   256504

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20210805.xsd EX-101.SCH 1939
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20210805_lab.xml EX-101.LAB 24335
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20210805_pre.xml EX-101.PRE 12681
7 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20210805_htm.xml XML 10531
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 211148246
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences